Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Yoshihiko Ooka, et al.
BMC Gastroenterology|March 11, 2023
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, et al.
Scientific Reports|November 2, 2021
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinomaYuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, et al.
Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
Anticancer Research|February 28, 2023
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 InhibitorsKeita Ogawa, Tetsuhiro Chiba, Masato Nakamura, et al.
BMJ Open|June 2, 2026
Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocolKeisuke Koroki, Masaru Wakatsuki, Sadahisa Ogasawara, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Journal of Cancer|June 17, 2022
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical ExperienceKeita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cellsTerunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Pageof 16